Table 1.
Antimicrobial susceptibility results of 55 CRKP clinical isolates
| Antimicrobial agents | MIC (μg/mL) | number of isolates (%) | ||||
|---|---|---|---|---|---|---|
| Range | MIC50 | MIC90 | S | I | R | |
| CTX | 256–> 256 | > 256 | > 256 | 0 (0.0) | 0 (0.0) | 55 (100) |
| CRO | 256–> 256 | > 256 | > 256 | 0 (0.0) | 0 (0.0) | 55 (100) |
| FEP | 128 – > 256 | > 256 | > 256 | 0 (0.0) | 0 (0.0) | 55 (100) |
| MEM | 8–> 256 | 256 | > 256 | 0 (0.0) | 0 (0.0) | 55 (100) |
| ATM | 2–> 256 | > 256 | > 256 | 1 (1.8) | 0 (0.0) | 54 (98.2) |
| FOS | 256–> 512 | > 512 | > 512 | 0 (0.0) | 0 (0.0) | 55 (100) |
| AK | 1–> 256 | > 256 | > 256 | 4 (7.3) | 0 (0.0) | 51 (92.7) |
| TGC | 1–8 | 2 | 8 | 22 (40.0) | 8 (14.5) | 25 (45.5) |
| PB | 0.25–1 | 0.5 | 0.5 | 55 (100) | 0 (0.0) | 0 (0.0) |
MIC50, minimum inhibitory concentration for 50% of the isolates; MIC90, minimum inhibitory concentration for 90% of the isolates
S susceptibility, I intermediate, R resistance
CTX cefotaxime, CRO ceftriaxone, FEP cefepime, MEM meropenem, ATM aztreonam, FOS fosfomycin, AK amikacin, TGC tigecycline, PB polymyxin B
The susceptibility profiles were analyzed according to the CLSI guidelines for CTX, CRO, FEP, MEM, ATM, FOS and AK, and EUCAST for PB and TGC